Source: Annual Congress 2006 - COPD therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. M. G. Halpin, S. Menjoge, K. Viel (Exeter, United Kingdom; Ridgefield, United States Of America; Ingelheim, Germany). Tiotropium reduces the risk of COPD exacerbation irrespective of its characterization by the treatment intervention. Eur Respir J 2006; 28: Suppl. 50, 4397

Member's Comments

No comment yet.

Related content which might interest you: Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 COPD exacerbations: impact and prevention Source: Breathe 2013; 9: 434-440 Year: 2013 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011 Decaf score for predicting treatment escalation in exacerbations of COPD Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019